The Food and Drug Administration called one Revlon product higher risk because of its potential to be contaminated with a known human carcinogen in the letter dated June 2. The details of the product and the potential contaminant were redacted from the public version of the letter.
Revlon didn’t answer questions from Bloomberg News about the product or contaminant, but said it stands by the safety of its products and is working with the FDA to ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.